Treatment of a delayed graft failure after allogeneic bone marrow transplantation with IL-3 and GM-CSF.
We report on the partial effectiveness of sequential IL-3 and GM-CSF administration, following an ineffective 5-day trial with G-CSF, in a case of delayed graft failure after allogeneic bone marrow transplantation. Therapy with these growth factors was followed by a prompt (within 2 days) increase of neutrophil count, suggesting the possibility of a priming effect due to the previous G-CSF administration. The potential usefulness of this growth factor schedule administration in the treatment of graft failures after allogeneic bone marrow transplantation requires confirmation in controlled trials.
Vannucchi
A M
AM
Division of Hematology, University of Florence, Ospedale di Careggi, Italy.
Bosi
A
A
Laszlo
D
D
Guidi
S
S
Saccardi
R
R
Rossi-Ferrini
P
P
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D006085:Graft Survival / Q000187:drug effects*; D006086:Graft vs Host Disease; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007377:Interleukin-3 / Q000627:therapeutic use*; D002955:Leucovorin / Q000008:administration & dosage; D016393:Lymphoma, B-Cell / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D011034:Podophyllotoxin / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D007155:Immunologic Factors; D007377:Interleukin-3; D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D011034:Podophyllotoxin; D008558:Melphalan; D002955:Leucovorin; D002330:Carmustine; D011241:Prednisone; D008727:Methotrexate